- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00272831
The Use of Cilostazol in Patients With Diabetic Nephropathy
A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese
Patients with type 2 diabetes have a long duration of disease for the development of complications. Among all complications, microangiopathic complications are major causes of mortality and morbidity in diabetic patients. In Asia, patients with type 2 diabetes are particularly susceptible to the development of kidney disease. Patients with diabetic kidney disease have more adverse metabolic profiles and increased risk of having other complications such as blindness, stroke, heart attack and nerve damage than those without. Despite receiving the best of care, the combined event rate of death, cardiovascular disease and end stage kidney disease in diabetic patients with renal impairment remained as high as 10% per year.
Cilostazol reduces platelet aggregation and prevents formation of blood clots. Furthermore, cilostazol treatment has been shown to reduce serum triglyceride concentrations and increase HDL-cholesterol levels. In this randomized placebo-controlled, double-blinded study, the investigators hypothesize that Cilostazol may reduce the rate of decline in renal function in Chinese patients with type 2 diabetes and mild to moderate renal impairment. Sixty patients will be randomised to receive either Cilostazol 100 mg twice daily or placebo for 12 months. The effect of Cilostazol on the progression of diabetic nephropathy, as defined by rates of decline in glomerular filtration rate, serum creatinine and urinary albumin excretion rate will be measured. The results will provide additional insight on the management of diabetic kidney disease which is prevalent among Chinese diabetic patients in Hong Kong.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Hypothesis:
Cilostazol reduces the rate of decline in renal function in Chinese patients with type 2 diabetes and mild to moderate renal impairment secondary to diabetic nephropathy.
Objectives:
To assess the suppressive effect of Cilostazol on the progression of diabetic nephropathy, as defined by rates of decline in glomerular filtration rate, serum creatinine and urinary albumin excretion rate.
The rising prevalence of diabetes in Asia imposes a heavy burden on the health care system. Given the increasingly early onset of disease, patients with type 2 diabetes have long duration of disease for the development of complications. Among all complications, microangiopathic complications are major causes of mortality and morbidity in diabetic patients. In Asia, patients with type 2 diabetes are particularly susceptible to the development of nephropathy. Among dialysis patients, the primary disease is diabetic nephropathy in about 40 to 50 % of patients. Despite the inhibition of the renin angiotensin system using either ACE inhibitor or AII receptor blocker (ARB) as well as introduction of tight glycaemic and blood pressure control, the prevalence of diabetic nephropathy remains high. More importantly, patients with nephropathy have more adverse metabolic profiles and increased risk of having other complications such as retinopathy, macrovascular diseases and neuropathy than those without. Indeed, according to the RENAAL Study, despite receiving the best of care, the combined event rate of death, cardiovascular disease and end stage renal disease in diabetic patients with renal impairment remained as high as 10% per year.
Cilostazol exerts antiplatelet, antithrombotic and vasodilating effects by inhibiting phosphodiesterase type 3 in platelets and vascular smooth muscle cells. Furthermore, cilostazol treatment has been shown to reduce serum triglyceride concentrations and increase HDL-cholesterol levels. In Japanese patients with type 2 diabetes, cilostazol therapy was associated with regression of carotid intimal media thickness and could prevent the onset of silent brain infarction. On the other hand, abnormal metabolism of prostaglandins in renal glomeruli has been postulated to modulate renal haemodynamics. Elevated levels of platelet-derived microparticles and soluble adhesion molecules may further contribute to the development of diabetic nephropathy. Cilostazol treatment had been shown to reduce serum levels of PMP, activated platelet subsets, soluble adhesion molecules and urinary excretion of thromboxane B2 in patients with type 2 diabetes. These changes were accompanied by a reduction in urinary albumin excretion and an increase in creatinine clearance.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male or female patients aged between 20 and 70 years
- Patients with Type 2 diabetic mellitus
- A fasting urinary albumin/creatinine ratio greater than or equal to 30 mg/mmol or 24 hour urinary albumin excretion greater than or equal to 300 mg/day in two urine collections during the baseline period
Two consecutive serum creatinine levels during baseline period which meet the following requirements:
- Women: between 80 umol/l and 250 umol/l (inclusive)
- Men: between 105 umol/l and 250 umol/l (inclusive)
- Written informed consent
Exclusion Criteria:
- Pregnancy
- Known allergy to cilostazol or aspirin
- Congestive heart failure (NYHA class III to IV)
- Severe liver impairment (greater than or equal to 3 times ULN of ALT)
- Serum potassium levels greater than or equal to 5.5 mmol/l on 2 consecutive specimens
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Placebo
|
1 tablett två gånger dagligen
|
Aktiv komparator: Cilostazol
Cilostazol 100 mg twice daily
|
Cilostazol 100 mg två gånger dagligen
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Doubling of serum creatinine level
Tidsram: 1 year
|
1 year
|
50% reduction in GFR (estimated by MDRD equation)
Tidsram: 1 year
|
1 year
|
GFR less than 15 ml/min/1.73m2
Tidsram: 1 year
|
1 year
|
Need for dialysis
Tidsram: 1 year
|
1 year
|
Death related to renal causes
Tidsram: 1 year
|
1 year
|
Fatal or severe bleeding
Tidsram: 1 year
|
1 year
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Composite cardiovascular endpoints (acute myocardial infarction, revascularisation procedures, heart failure or unstable angina or arrhythmia) requiring hospital admissions, lower extremity amputation)
Tidsram: 1 year
|
1 year
|
Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department
Tidsram: 1 year
|
1 year
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Peter C Tong, PhD, MBBS, Chinese University of Hong Kong
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Störningar i glukosmetabolism
- Metaboliska sjukdomar
- Urologiska sjukdomar
- Sjukdomar i det endokrina systemet
- Diabetes mellitus
- Diabetes mellitus, typ 2
- Njursjukdomar
- Diabetiska nefropatier
- Diabeteskomplikationer
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Vasodilaterande medel
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Enzyminhibitorer
- Fibrinolytiska medel
- Fibrinmodulerande medel
- Trombocytaggregationshämmare
- Neuroprotektiva medel
- Skyddsmedel
- Bronkdilaterande medel
- Anti-astmatiska medel
- Andningsorgan
- Fosfodiesterashämmare
- Fosfodiesteras 3-hämmare
- Cilostazol
Andra studie-ID-nummer
- PWH 2005-146-T
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes mellitus, typ 2
-
Mathias Ried-LarsenOkändDiabetes mellitus, typ 2 | Typ 2-diabetes mellitus | Diabetes typ 2 | Typ 2 diabetes mellitusDanmark
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
-
Hanmi Pharmaceutical Company LimitedOkändTyp 2 diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
Caroline M KistorpRigshospitalet, Denmark; Herlev and Gentofte Hospital; Danish Heart FoundationAvslutadTyp 2 diabetes mellitusDanmark
-
TheracosAvslutadTyp 2 diabetes mellitusFörenta staterna
-
Biocon LimitedAvslutadJämförelse av insulin tregopil (IN-105) med insulin aspart hos patienter med typ 2-diabetes mellitusTyp 2 diabetes mellitusIndien
-
Chong Kun Dang PharmaceuticalOkändTyp 2 diabetes mellitusKorea, Republiken av
-
PegBio Co., Ltd.AvslutadTyp 2 diabetes mellitusKina
-
Chong Kun Dang PharmaceuticalAvslutadTyp 2 diabetes mellitusKorea, Republiken av
-
Daiichi Sankyo Co., Ltd.AvslutadTyp 2 diabetes mellitusJapan
Kliniska prövningar på Placebo
-
SamA Pharmaceutical Co., LtdOkändAkut bronkit | Akut övre luftvägsinfektionKorea, Republiken av
-
National Institute on Drug Abuse (NIDA)AvslutadAnvändning av cannabisFörenta staterna
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAvslutadManliga försökspersoner med typ II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAvslutadFarmakokinetik | SäkerhetsfrågorStorbritannien
-
Regado Biosciences, Inc.AvslutadFrisk volontärFörenta staterna
-
Texas A&M UniversityNutraboltAvslutadGlucose and Insulin Response
-
Longeveron Inc.AvslutadHypoplastiskt vänsterhjärtsyndromFörenta staterna
-
ItalfarmacoAvslutadBeckers muskeldystrofiNederländerna, Italien
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AvslutadVassleproteintillskott associerat med motståndsträning på hälsoindikatorer hos tränade äldre kvinnorFriska | Kroppssammansättning